Encision Inc. (ECIA)
USD 0.35
(0.0%)
USD 0.35
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 1.33 Million USD | 23.1% |
| 2023 | 1.08 Million USD | -6.15% |
| 2022 | 1.15 Million USD | -42.39% |
| 2021 | 2 Million USD | 11.71% |
| 2020 | 1.79 Million USD | 2296.39% |
| 2019 | 74.82 Thousand USD | 638.75% |
| 2018 | 10.12 Thousand USD | -96.32% |
| 2017 | 275 Thousand USD | -34.05% |
| 2016 | 417 Thousand USD | 152.73% |
| 2015 | 165 Thousand USD | 35.61% |
| 2014 | 121.67 Thousand USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | -100.0% |
| 2011 | 435 Thousand USD | 24.29% |
| 2010 | 350 Thousand USD | 83.3% |
| 2009 | 190.94 Thousand USD | -68.49% |
| 2008 | 606 Thousand USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | -100.0% |
| 2004 | 32 Thousand USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 1.8 Million USD | 83.37% |
| 2024 Q1 | 986 Thousand USD | -8.96% |
| 2024 FY | 1.33 Million USD | 23.1% |
| 2024 Q3 | 1.42 Million USD | -21.0% |
| 2024 Q4 | 1.33 Million USD | -6.66% |
| 2023 Q3 | 977 Thousand USD | -11.31% |
| 2023 Q1 | 1.07 Million USD | -7.11% |
| 2023 FY | 1.08 Million USD | -6.15% |
| 2023 Q4 | 1.08 Million USD | 10.85% |
| 2023 Q2 | 1.1 Million USD | 2.76% |
| 2022 Q1 | 1.92 Million USD | -3.74% |
| 2022 Q2 | 1.31 Million USD | -31.69% |
| 2022 Q3 | 1.23 Million USD | -6.23% |
| 2022 Q4 | 1.15 Million USD | -6.56% |
| 2022 FY | 1.15 Million USD | -42.39% |
| 2021 FY | 2 Million USD | 11.71% |
| 2021 Q2 | 2.53 Million USD | 17.18% |
| 2021 Q1 | 2.16 Million USD | 20.75% |
| 2021 Q4 | 2 Million USD | 37.85% |
| 2021 Q3 | 1.45 Million USD | -42.73% |
| 2020 Q4 | 1.79 Million USD | 20.58% |
| 2020 Q2 | 1.31 Million USD | -4.63% |
| 2020 Q3 | 1.48 Million USD | 12.74% |
| 2020 FY | 1.79 Million USD | 2296.39% |
| 2020 Q1 | 1.38 Million USD | 1748.41% |
| 2019 Q4 | 74.82 Thousand USD | 1.53% |
| 2019 Q3 | 73.69 Thousand USD | 60.97% |
| 2019 Q1 | 87 Thousand USD | 759.0% |
| 2019 FY | 74.82 Thousand USD | 638.75% |
| 2019 Q2 | 45.77 Thousand USD | -47.38% |
| 2018 Q1 | 207 Thousand USD | -24.73% |
| 2018 Q3 | 17.72 Thousand USD | -30.0% |
| 2018 Q4 | 10.12 Thousand USD | -42.86% |
| 2018 FY | 10.12 Thousand USD | -96.32% |
| 2018 Q2 | 25.32 Thousand USD | -87.77% |
| 2017 Q2 | 368 Thousand USD | 8.55% |
| 2017 Q3 | 284 Thousand USD | -22.83% |
| 2017 FY | 275 Thousand USD | -34.05% |
| 2017 Q1 | 339 Thousand USD | -18.71% |
| 2017 Q4 | 275 Thousand USD | -3.17% |
| 2016 Q4 | 417 Thousand USD | 21.22% |
| 2016 FY | 417 Thousand USD | 152.73% |
| 2016 Q1 | 157 Thousand USD | -4.85% |
| 2016 Q2 | 116 Thousand USD | -26.11% |
| 2016 Q3 | 344 Thousand USD | 196.55% |
| 2015 Q4 | 165 Thousand USD | -14.51% |
| 2015 FY | 165 Thousand USD | 35.61% |
| 2015 Q2 | 145 Thousand USD | -12.12% |
| 2015 Q1 | 165 Thousand USD | 35.61% |
| 2015 Q3 | 193 Thousand USD | 33.1% |
| 2014 Q1 | 894 Thousand USD | 0.0% |
| 2014 FY | 121.67 Thousand USD | 0.0% |
| 2014 Q4 | 121.67 Thousand USD | -42.33% |
| 2014 Q3 | 211 Thousand USD | -69.24% |
| 2014 Q2 | 686 Thousand USD | -23.27% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2012 Q1 | 635 Thousand USD | 45.98% |
| 2012 Q4 | - USD | -100.0% |
| 2012 FY | - USD | -100.0% |
| 2012 Q2 | 691.01 Thousand USD | 8.82% |
| 2012 Q3 | 756.23 Thousand USD | 9.44% |
| 2011 Q4 | 435 Thousand USD | -2.76% |
| 2011 Q3 | 447.36 Thousand USD | -23.04% |
| 2011 FY | 435 Thousand USD | 24.29% |
| 2011 Q2 | 581.26 Thousand USD | -10.57% |
| 2011 Q1 | 650 Thousand USD | 85.71% |
| 2010 Q1 | 275 Thousand USD | 44.02% |
| 2010 Q3 | 275 Thousand USD | 22.22% |
| 2010 FY | 350 Thousand USD | 83.3% |
| 2010 Q2 | 225 Thousand USD | -18.18% |
| 2010 Q4 | 350 Thousand USD | 27.27% |
| 2009 Q2 | 505.03 Thousand USD | 16.67% |
| 2009 Q4 | 190.94 Thousand USD | -4.02% |
| 2009 Q3 | 198.94 Thousand USD | -60.61% |
| 2009 FY | 190.94 Thousand USD | -68.49% |
| 2009 Q1 | 432.87 Thousand USD | -28.57% |
| 2008 Q1 | - USD | 0.0% |
| 2008 FY | 606 Thousand USD | 0.0% |
| 2008 Q3 | 280 Thousand USD | 0.0% |
| 2008 Q4 | 606 Thousand USD | 116.43% |
| 2008 Q2 | 280 Thousand USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2005 FY | - USD | -100.0% |
| 2005 Q3 | 19.61 Thousand USD | -16.66% |
| 2005 Q1 | 27.45 Thousand USD | -14.2% |
| 2005 Q4 | - USD | -100.0% |
| 2005 Q2 | 23.53 Thousand USD | -14.28% |
| 2004 Q2 | 23.53 Thousand USD | 0.0% |
| 2004 FY | 32 Thousand USD | 0.0% |
| 2004 Q3 | 19.61 Thousand USD | -16.66% |
| 2004 Q4 | 32 Thousand USD | 63.16% |
| 2004 Q1 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| American Medical Technologies Inc. | 500 Thousand USD | -166.64% |
| Ansell Limited | 855.59 Million USD | 99.844% |
| Ansell Limited | 857.2 Million USD | 99.844% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 22.41 Million USD | 94.051% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | 20.93 Thousand USD | -6268.292% |
| Psykey, Inc. | 1.01 Million USD | -31.922% |
| ConvaTec Group Plc | 1.31 Billion USD | 99.898% |
| ConvaTec Group Plc | 1.31 Billion USD | 99.898% |
| Golden Valley Development, Inc | - USD | -Infinity% |
| Hear AtLast Holdings, Inc. | 2.3 Million USD | 42.254% |
| Innovative MedTech Inc. | 1.87 Million USD | 29.018% |
| LifePoint, Inc. | 446.74 Thousand USD | -198.429% |
| Medite Cancer Diagnostics, Inc. | 5.39 Million USD | 75.284% |
| Paradigm Medical Industries, Inc. | 2.18 Million USD | 39.095% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | - USD | -Infinity% |
| Reflect Scientific, Inc. | 242.64 Thousand USD | -449.448% |
| SmileDirectClub, Inc. | 871.79 Million USD | 99.847% |
| Sector 10, Inc. | 164 Thousand USD | -712.928% |
| Shandong Weigao Group Medical Polymer Company Limited | 674.01 Million USD | 99.802% |
| SheerVision, Inc. | 75 Thousand USD | -1677.603% |
| United Health Products, Inc. | 755.98 Thousand USD | -76.352% |
| Vasamed, Inc. | 23.45 Thousand USD | -5585.296% |
| Wearable Health Solutions, Inc. | 2.76 Million USD | 51.824% |
| Yubo International Biotech Limited | 790.49 Thousand USD | -68.653% |